Zalicus
SITE MAP   |   CAREERS   |   CONTACT   |   
Investors and Media
Webcast ImageWebcast
Epirus and Zalicus Merger Agreement (Replay)
04/16/14 at 8:30 a.m. ET
Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary product candidates targeting pain, including Z944, a T-type calcium channel modulator for chronic and acute pain and our Nav 1.7 channel modulator program for chronic or acute pain. We have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease.
ZLCS (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.35
Change (%) Stock is Up 0.32 (31.07%)
Volume13,618,861
Data as of 04/16/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
04/16/14Zalicus and Epirus Announce Merger AgreementPrinter Friendly Version
04/01/14Zalicus to Present at AACR 2014 Annual MeetingPrinter Friendly Version
03/13/14Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.